Third quarter 2020 financial report

29. Oct 2020 | 2 min read

Moss, 29 October 2020

Gentian Diagnostics AS announces its results for the third quarter of 2020. The highlights include:

  • Sales revenue for the first nine months of MNOK 46.1 representing 36 % growth (24 % adjusted for currency effects) compared to the same period last year
  • Gentian’s Swedish distribution subsidiary, Gentian Diagnostics AB, has had a sales growth from third party products of 52 % YTD 2020 compared to the same period last year
  • Scientific Advisory Board for NT-proBNP (formerly called G-1001) Established
  • Study confirms significantly elevated levels of calprotectin in patients with severe COVID-19, which is an opportunity for our GCAL® assay

Please find the report and results presentation here:

GDAS Interim Report 3Q 2020
GDAS Interim Presentation 3Q 2020

 

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 516640
UtstederID: GENT-ME
Marked: Merkur Market

You may also read


Nov 05, 2020 - Julie

Gentian Diagnostics divests its subsidiary PreTect AS

Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS to Mel-Mont Medical, Inc...

Oct 22, 2020 - Julie

Presentation of 2020 third quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2020 third quarter results on October 29th at 10.00 am.